Older people are frequently under-served by clinical research. Study designs, eligibility criteria and research delivery approaches can make participation difficult, limiting the evidence available to inform treatment decisions and healthcare policy.

As a result, older people, carers, clinicians, regulators and policymakers often lack relevant evidence on the benefits and harms of treatments.

Researchers at NIHR Biomedical Research Centre (BRC): Newcastle helped lead the NIHR INCLUDE project, which developed a roadmap and best-practice guidelines for improving inclusion of under-served groups in clinical research. The team applied these guidelines in the MET-PREVENT trial, demonstrating how research can be designed and delivered to enable participation by older people living with frailty and multiple long-term conditions.

Impact at a glance

  • Led development of the NIHR INCLUDE roadmap for the inclusion of under-served groups in clinical research;
  • Produced best-practice guidance to support the inclusion of older people in research;
  • Contributed to NIHR adopting recommendations to require inclusion plans within research funding applications;
  • Demonstrated how inclusive trial design can be delivered through the MET-PREVENT study;
  • Recruited the MET-PREVENT trial to target and achieved a 97% completion rate over four months;
  • Successfully included people living with frailty, multiple long-term conditions and higher levels of mobility impairment than are usually represented in clinical trials;
  • Embedded patient and public involvement throughout trial design, delivery and dissemination.

Developing inclusive practices to research

Working with NIHR Research Delivery Network (RDN) colleagues, NIHR BRC researchers produced the NIHR INCLUDE roadmap to support the inclusion of under-served groups in clinical research. The roadmap provided the foundation for a series of guidance documents covering specific groups, including ethnic minority groups, adults lacking capacity, and older people – guidance that NIHR BRC researchers led with colleagues from the RDN and the British Geriatrics Society.

The guidance has been promoted widely, including through training delivered to research ethics committees, and is already being used by clinical trials.
NIHR has adopted recommendations from the INCLUDE project to mandate inclusion plans in funding applications.

 

INCLUDE in practice

NIHR BRC researchers applied the roadmap principles within the MET-PREVENT randomised trial, which investigated metformin in older people living with sarcopenia and frailty. Drawing on lessons from the earlier NIHR-funded LACE sarcopenia trial, the study was designed to maximise participation by older people. Inclusion and exclusion criteria were minimised, study assessments were streamlined, and recruitment used multiple routes including the SarcNet registry and SarcScreen routine data record, supported by a two-step screening process.

Study delivery was designed to be flexible, with many visits conducted in participants' homes by an RDN-supported community delivery team working alongside the NIHR Clinical Research Facility (CRF): Newcastle.

The trial recruited to target and achieved a completion rate of 97% over the four-month study period, despite participants living with frailty, multiple long-term conditions and higher levels of mobility impairment than are usually included in clinical trials.

Patient and public involvement and engagement (PPIE) was embedded throughout the study, from conception and design, through trial management, to dissemination, providing a model for effective co-production of research.

 

Benefits for research, practice and policy

Patients and carers benefit from better designed studies that are easier to participate in and therefore more likely to generate evidence relevant to older people living with sarcopenia and frailty.

Clinicians and researchers can draw on established guidance and practical examples when designing and delivering research involving older people, supporting the generation of more relevant evidence, treatments and outcomes.

Industry and regulators benefit from clearer examples of how participants can be recruited and retained in a challenging research area, helping generate evidence to support decision-making and reducing barriers to research investment.

 

Building on the lessons from INCLUDE and MET-PREVENT

The main findings from MET-PREVENT have been presented at scientific conferences, shared with trial participants and showcased through wider BRC and NIHR events, including a joint NIHR-Korea symposium on smart clinical trials in 2024.

The main results have been published in The Lancet Healthy Longevity, accompanied by a podcast to widen the dissemination. Researchers are also preparing further publications describing the trial's innovative recruitment approaches and have shared these findings with clinical trials methodology and ageing research communities, as well as NIHR Patient and Public Involvement and Engagement groups. Findings on how to improve recruitment to sarcopenia trials have led to consultancy with industry partners.
The results from MET-PREVENT excluded any benefit of metformin and highlighted significant side-effects in this vulnerable population.

The team is extending this work through new initiatives, including the REVITALiSE experimental medicine sarcopenia platform trial and research exploring how study information can be communicated more effectively to older trial participants.

Researchers also continue to promote the INCLUDE roadmap through NIHR networks, talks and collaborative work with other parts of NIHR infrastructure including the NIHR RDN.

A key lesson from both INCLUDE and MET-PREVENT has been the importance of involving patients and the public from the earliest stages of research design and delivery. The work has also highlighted the value of building an engaged community of public contributors, researchers and stakeholders to support the long-term improvement of inclusion in clinical research.

Improving inclusion of under-served groups in clinical research

Guidance from the NIHR INCLUDE project. 

More details